Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

The federal government has announced the results of the latest round of Medicare drug price negotiations: 15 lower drug prices for Medicare to go into effect in 2027. Medicare will get a 71% discount ...

The latest round of Medicare price cuts affect 15 drugs, including Xtandi, an older prostate cancer drug from Pfizer and Astellas Pharma Inc. that will face a 48% discount off its 2024 list price. GSK ...

Novo Nordisk NOVO.B-1.06%decrease; red down pointing triangle filed for U.S. approval of a higher dose of its Wegovy weight-loss injection, with a decision expected within a month or two. The Danish ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription drugs, including popular weight-loss medications Ozempic and Wegovy, asthma ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med ...

Trump and Novo struck a deal earlier this month that Medicare would pay $245 per month for Ozempic and Wegovy under the administration’s attempt to lower US drug costs by tying them to international ...

The new prices will take effect in 2027, and the negotiated prices include a monthly cost of $274 for Novo Nordisk’s (NYSE: NVO) popular GLP-1 drug, semaglutide, sold as Wegovy, Ozempic, and Rybelsus.

Medicare will pay billions of dollars less in 2027 for 15 drugs, including major medicines for cancer, asthma and metabolic conditions, after completing the second annual round of price negotiations ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases. By Gina Kolata Gina Kolata has ...